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ABSTRACT
Objective Copy number variants (CNVs) have been
associated with the risk to develop multiple autoimmune
diseases. Our objective was to identify CNVs associated
with the risk to develop psoriatic arthritis (PsA) using a
genome-wide analysis approach.
Methods A total of 835 patients with PsA and 1498
healthy controls were genotyped for CNVs using the
Illumina HumanHap610 BeadChip genotyping platform.
Genomic CNVs were characterised using CNstream
analysis software and analysed for association using the
χ2 test. The most signiﬁcant genomic CNV associations
with PsA risk were independently tested in a validation
sample of 1133 patients with PsA and 1831 healthy
controls. In order to test for the speciﬁcity of the variants
with PsA aetiology, we also analysed the association to
a cohort of 822 patients with purely cutaneous psoriasis
(PsC).
Results A total of 165 common CNVs were identiﬁed
in the genome-wide analysis. We found a highly
signiﬁcant association of an intergenic deletion between
ADAMTS9 and MAGI1 genes on chromosome 3p14.1
(p=0.00014). Using the independent patient and control
cohort, we validated the association between ADAMTS9-
MAGI1 deletion and PsA risk (p=0.032). Using next-
generation sequencing, we characterised the 26 kb
associated deletion. Finally, analysing the PsC cohort we
found a lower frequency of the deletion compared with
the PsA cohort (p=0.0088) and a similar frequency to
that of healthy controls (p>0.3).
Conclusions The present genome-wide scan for CNVs
associated with PsA risk has identiﬁed a new deletion
associated with disease risk and which is also differential
from PsC risk.
INTRODUCTION
Psoriatic arthritis (PsA) is a chronic inﬂammatory
arthritis that affects 10–30% of patients with
psoriasis.1 2 To date, genome-wide association
studies (GWAS) as well as candidate gene studies
have shown that both diseases share a substantial
genetic component. However, sibling recurrence
rates (λs) are much higher for PsA than psoriasis
(PsA λs∼37 vs psoriasis λs∼7),3–5 indicating that
additional, perhaps disease-speciﬁc, risk factors
need to be identiﬁed.
GWAS based on single-nucleotide polymorph-
isms (SNPs) have been highly successful in identify-
ing >30 loci associated with psoriasis and PsA
susceptibility.6–8 The cumulative risk exerted by
these loci, however, is <50%,9 and additional
genetic factors still need to be identiﬁed in order to
explain the missing heritability. Strategies to com-
plete the characterisation of the genetic architecture
of psoriasis and PsA include the use of large sample
sizes or the combination of different studies
through metaanalysis,10 the deep sequence charac-
terisation to identify rare variants with large effect
sizes11 and, also, the analysis of other types of
genetic variation that cannot be completely cap-
tured by SNP-based genotyping platforms such as
copy number variants (CNVs).
CNVs are fragments of DNAwith sizes that range
from hundreds of bases to several megabases, and
that can either be absent (ie, deletions), repeated a
certain number of times (ie, ampliﬁcations) or even
rearranged.12 Psoriasis was one of the ﬁrst chronic
inﬂammatory diseases where CNVs were found to
be associated with the disease risk. The ampliﬁca-
tions of the β-defensin genes on 8p23.1 region13
and the deletion affecting LCE3B and LCE3C
genes14 have been clearly associated with psoriasis
aetiology. The association of these CNVs with PsA
aetiology, however, is still not clear,2 15 suggesting
that they could participate in the chronic inﬂamma-
tory processes in the skin rather than in the patho-
logical process occurring in the joint.
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In the present study, we have performed the ﬁrst genome-
wide analysis of CNVs in PsA. We have ﬁrst analysed a discovery
panel of 835 patients with PsA and 1498 healthy controls from
the Spanish population using a microarray platform. The CNVs
showing a more signiﬁcant association to PsA risk were subse-
quently selected and validated in an independent cohort of
1133 patients with PsA and 1831 healthy controls. In order to
test for the speciﬁcity of the CNV association with PsA aeti-
ology, we have also analysed a set of 822 psoriasis patients
without arthritis. Using this approach, we have identiﬁed a new
deletion associated with PsA risk that is not associated with
purely cutaneous psoriasis (PsC).
PATIENTS AND METHODS
Study subjects
To identify new loci associated with psoriasis risk using the
GWAS approach, we recruited 835 patients with PsA and 1498
healthy controls from the Spanish population. Patient and
control individuals were obtained by the Immune-Mediated
Inﬂammatory Disease Consortium (IMIDC).16 The IMIDC is a
Spanish biomedical research collaboration project that includes
biomedical and clinical researchers on rheumatology, dermatol-
ogy and gastroenterology, and that is devoted to the study of
prevalent autoimmune diseases. In the present study, a total of
26 rheumatology departments—15 in the GWAS stage and 11
additional in the replication stage—and 11 dermatology depart-
ments from different university hospitals in Spain participated
in the patient recruitment and clinical data collection. All
patients with PsA included in this study had a clinical diagnosis
made by a consultant rheumatologist. All patients with PsA were
diagnosed according to the Classiﬁcation Criteria for Psoriatic
Arthritis criteria,17 were >18 years old—although the disease
could have started earlier in life—and had at least 1 year of evo-
lution of the disease. Exclusion criteria for the present study
were (i) presence of any other inﬂammatory joint disease, (ii)
presence of any inﬂammatory bowel disease and (iii) positivity
of rheumatoid factor.
Control individuals for the GWAS stage were recruited from
blood bank donors attending at 13 hospitals from different
regions in Spain in collaboration with the Spanish National
DNA Bank (http://www.bancoadn.org). Eligible individuals were
screened for the presence of PsA or any other autoimmune dis-
order, as well as for history of autoimmune disorders in ﬁrst-
degree relatives, and positive individuals were discarded from
this study. Additionally, in order to increase the ‘hypernormal-
ity’ of the control cohort,18 only individuals who were
>30 years old were included. In total, 1498 controls, 40% of
whom were women, were analysed in the GWAS. Of note,
>96% of the control individuals were >40 years old at the time
of recruitment.
All patients and controls in the GWAS and replication cohorts
were Caucasian European. In those cases where any of the four
grandparents was not born in Spain, the individual was dis-
carded from the study. The DNA samples from patients and
controls in both stages of the study were obtained from whole
blood samples.
A total of 1131 patients with PsA and 1831 controls were
used to validate the most signiﬁcant loci identiﬁed in the GWAS
phase. Both cohorts were collected using the same clinical and
epidemiological selection criteria as for the GWAS. Additionally,
a sample of 822 patients diagnosed with psoriasis and without
PsA (ie, PsC) was also analysed in the validation phase. All
patients with PsC were diagnosed and recruited by a consultant
dermatologist participating in the IMID Consortium.2 Psoriasis
patients with plaque psoriasis affecting torso and/or extremities
and with at least one year of duration were included. Patients
with a single clinical localisation of plaque psoriasis (ie, scalp,
face, palmoplantar), with exclusively inverse plaque psoriasis or
with an inﬂammatory bowel disease, were excluded from the
study. Finally, psoriasis patients diagnosed with PsA by a
rheumatologist were excluded from this group.
Genome-wide CNV analysis
We performed a CNV genome-wide scan by using Illumina
610Quad Beadchips (Illumina, San Diego, California, USA),
which contains a total of 620 901 probes. Sample genotyping
was performed at the HudsonAlpha Institute for Biotechnology
(Alabama, USA). After excluding mitochondrial as well as X and
Y chromosome SNPs, a total of 600 470 probes were considered
for GWAS CNVanalysis.
Before proceeding to perform PsA risk analysis, we performed
several quality control analysis steps. First, only those samples
that had a >95% genotype completion rate were considered for
analysis (99% of samples). Second, we used the SNPs genotype
information to estimate the main axes of variation using the
principal component analysis implemented in the Eigenstrat
software.19 With this approach, individuals showing a high devi-
ation in any of the 10 top principal axes of variation were con-
sidered outliers and were consequently removed (>6 SDs from
the centre of each component, n=42 outliers). Online supple-
mentary ﬁgure S1 shows the patient with PsA and control distri-
butions according to the ﬁrst and second principal components
after excluding the outliers.
Since CNV genotyping is subject to more technical biases
than SNP genotyping, several additional quality control ﬁlters
must be applied to the GWAS data. Following previous GWAS
CNV studies,20 samples with a substantial deviation from the
mean log Ratio (|m log R ratio| > 0.1) or with an excessive
variability (σ log R ratio > 0.2), were excluded (n=556 indivi-
duals, 23.8%). After applying all the quality control ﬁlters, a
total of 658 patients with PsA and 1063 controls were ﬁnally
available for the CNV GWAS. Online supplementary ﬁgure S2
shows a schematic representation of the global CNV analysis
workﬂow.
CNV identiﬁcation and genotyping was performed using
CNstream software (ﬁgure 1A).21 CNstream ﬁrst applies a nor-
malisation procedure to control for the presence of potential
intensity biases from samples processed at different time points
(ie, batch normalisation). It then applies a second normalisation
step to minimise the difference of sensitivity between the two
colour channels used to analyse each probe (ie, intensity normal-
isation).22 Once the data are normalised, CNstream jointly ana-
lyses sets of consecutive probes (n=5 in this study) to identify
the presence of a CNV in a particular region of the genome and
generate a genotype call for each individual.
After genome-wide CNV identiﬁcation and calling, the associ-
ation with disease risk was tested using the genotypic χ2 test. In
the case of low-frequency CNVs (minor allele frequency <5%),
the genotype counts for CNV homozygous (0N) as well as indi-
viduals with 1 deletion (1N) were merged in a single
CNV-positive group and compared with non-CNV carriers
(2N). Statistical association analyses were performed using R
software V.3.0.1.23
Targeted sequencing of ADAMTS9-MAGI1 locus
In order to characterise the chromosome 3q14.2 sequence har-
bouring the deletion associated with PsA risk in the CNV
GWAS, we performed a targeted resequencing analysis in
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selected samples from the discovery phase. Next-generation
sequencing was performed at the HudsonAlpha Institute for
Biotechnology (Alabama, USA). A total of 100 patients with PsA
and 100 control individuals were selected for sequencing of
ADAMTS9-MAGI1 locus. The individuals were selected so that
deletion carriers and non-carriers—as determined by GWAS
genotyping—were equally present in both groups.
Consequently, 100 sequenced individuals carried one or two
deletions (ie, 1N or 0N) and 100 individuals had no deletion
(ie, 2N individuals).
The Illumina sequencing platform (Illumina, San Diego, USA)
was used to characterise the deletion sequence. In order to iden-
tify yet undiscovered variants in the two ﬂanking genes that
could be responsible for the observed association with PsA risk,
we also sequenced ADAMTS9 and MAGI1 genes and their 50
and 30 ﬂanking sequences. First, the DNA quality of these
samples was assessed by running 1–3 mL on a 1% agarose gel
that contained 1× Sybr Green I dye (Life Technologies, USA).
Next we followed the CATCH-Seq procedure we reported
recently.24 In brief, we puriﬁed CTD-2216H2, CTD-2255G2,
CTD-2517E23, RP11-841H13, RP11-1080G20, RP11-411F5
and RP11-257J13 BAC DNAs that are commercially available
(Life Technologies). BAC DNAs were pooled by percentage of
the total target size (1.1 Mb) according to a 4 mg total input
mass, and the pool was sheared by E220 Covaris sonication.
Linkers containing T7 promoter sequences were ligated to
sheared BAC fragments, and biotinylated RNA probes were
synthesised by in vitro transcription using a MEGAscript kit
(Ambion) and biotin-11-UTP (Life Technologies) with T7-BAC
fragments as template. Illumina libraries were prepared accord-
ing to standard protocol using 24 inline barcoded adapters.
For capture of library within the ADAMTS9/MAGI1 chromo-
some 3 region, hybridisation reactions were assembled with 4
barcoded libraries (125 ng of each), 20 mg of Cot-1 DNA (Life
Technologies), 236 ng probe, 20 U SUPERase-In (Life
Technologies) and 2× hybridisation buffer in a ﬁnal volume of
Figure 1 ADAMTS9-MAGI1 deletion characterisation. (A) Map of chromosome 3p14.1 region showing ADAMTS9 and MAGI1 genes (blue
segments), and the intergenic deletion (green rectangle) associated with psoriatic arthritis (PsA) risk. The horizontal red lines indicate the location of
the two Taqman assays (Hs03225015_cn and Hs03225295_cn, red vertical lines) used to genotype the deletion. (B) CNStream deletion calling using
multiple probes within the deletion sequence. This software method combines the copy number estimation of consecutive probes (left: probe at
chr3:65 191 847 pb; right: probe at chr3: 65 196 123 pb). (C) Log2 intensity reads of six individuals for the chromosome 3 region harbouring the
deletion. Starting from the top, the ﬁrst two individuals show the characteristic drop in intensity corresponding to hemizygous (ie, 1N) individuals.
The third, fourth and sixth individuals show the expected log2 reads of a 2N individual, with most of the intensities centred around 0. Finally, the
ﬁfth individual clearly shows the presence of an individual homozygous for the deletion, with no sequence reads mapping to this region of the
chromosome. (D) Sequence of the reference and deletion alleles. Physical coordinates are on the reference human genome (build 37).
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26 mL incubated at 65°C for 70 h. Hybridisation reactions were
incubated with 25 μL MyOne Streptavidin C1Dynabeads (Life
Technologies) for 30 min with frequent pulse vortexing. Bead
captures were washed twice for 15 min each at room tempera-
ture in 0.5 mL wash buffer 1 (1×SSC, 0.1% SDS), followed by
four stringency wash steps at 65°C in 0.5 mL preheated wash
buffer 2 (0.1×SSC, 0.1% SDS) for 10 min each. Captured
libraries were eluted in 50 μL 0.1 M NaOH and neutralised in
70 μL 1 M Tris pH 7.5. Final libraries were cleaned with 1.8×
solid-phase reversible immobilisation beads and eluted in 33 mL
water for assembly of library ampliﬁcation PCR containing 1 mL
Platinum Taq (Life Technologies) and 5 mL 5 M betaine (Sigma)
in 50 mL reactions (98°C 1 min, 95°C 30 s and 62°C 3.5 min
for 20 cycles). Final 4-plex library concentrations were deter-
mined by KAPA QPCR (KAPA Biosystems) and adjusted to
15 nM each. Stock 4-plex libraries were pooled appropriately
for ﬁnal 24-plex libraries each for a single lane on HiSeq2000
sequencer (Illumina) using 50 bp paired end conditions.
Sequencing reads from individual samples were demuxed
based on inline barcode sequences and aligned to the human
reference genome (hg19) with BWA.25 Relative read depth was
calculated as the number of bases mapped to 100 bp windows
per total bases mapped for a given sample. Then a log2 ratio
between each sample at each 100 bp window to the mean of all
samples at that window was used to plot a normalised read
depth, representing the read depth relative to a theoretical
diploid reference. The plots of these normalised read depths
across the locus were used to conﬁrm the presence of the dele-
tion (ﬁgure 1B).
CNV replication analysis
Replication genotyping was performed using the TaqMan
Genotyping System (Applied Biosystems, Foster City, California,
USA). Two pre-designed Taqman CNV assays Hs03225015_cn
and Hs03225295_cn were found to be located within the esti-
mated deletion boundaries. In order to validate the two assays,
we genotyped the group of 200 individuals that were previously
used to sequence the deletion. The correspondence between the
calls of the two CNVs between the Taqman and sequencing ana-
lysis was 100%. Consequently, we used the two Taqman assays
to genotype the ADAMTS9-MAGI1 deletion in an independent
group of 1133 patients with PsA, 1831 healthy controls and
822 patients with PsC. Quality control measures similar to the
GWAS were applied, including genotyping call rate >95%,
sample completion rate >90% and Hardy–Weinberg disequilib-
rium p value of control group p>0.001. The CNV genotype
concordance between the two Taqman assays was >99%.
Meta-analysis of the GWAS and replication association statistics
was performed using METAL software.26
RESULTS
CNV identiﬁcation and genotyping
Table 1 summarises the main features of the GWAS and replica-
tion PsA patient cohorts.
Using a total of 658 patients with PsA and 1063 healthy con-
trols, we identiﬁed a total of 2674 CNV segments. After
merging segments belonging to the same genomic region (dis-
tance <10 kb and/or r2>0.9), we performed the genotype
calling in a total of 1953 different CNV regions. Among them,
165 CNVs appeared in >5% of the samples and were subse-
quently used to test for association with PsA risk. Online supple-
mentary table S1 describes the characteristics of these CNVs.
CNV GWAS for PsA risk
Using the group of common CNVs, we performed a GWAS for
PsA risk. We found a very strong association signal at an inter-
genic deletion located between the HLA-C and HLA-B genes
(p=5.37e-11, OR (95% CI) 2.08 (1.47 to 2.95), MAF=0.18,
ﬁgure 2). Since HLA-C locus is an established risk locus for PsA
we sought to estimate the association of the deletion after cor-
recting for the HLA haplotypes associated with psoriasis risk as
recently described.27 We found that, after correcting for
HLA-C*0602 and HLA-B*3801 alleles, the deletion was no
longer associated with PsA risk (p=0.81, see online supplemen-
tary table S2). Consequently, this CNV was considered a proxy
for the HLA allele association and was not included for
replication.
We also found another highly signiﬁcant association for a
deletion located in the chromosome 3q14.2 intergenic region,
between ADAMTS9 and MAGI1 genes (p=0.00014, OR (95%
CI) 1.94 (1.37 to 2.75), MAF=0.04, ﬁgure 2). This genomic
region had not been previously associated to any SNP-based
Figure 2 Plot of the copy number variant (CNV) genome-wide
association studies results. The −log10 p values (y-axis) are plotted for
each of the CNVs identiﬁed by CNSstream. Each chromosome is coded
in a different colour. The probes mapping the intergenic deletion in
HLA-C/-B locus in chromosome 6 (light blue dots) were found to have a
high signiﬁcance; however, after correcting for HLA-C and HLA-B alleles
this association disappeared. In chromosome 3, an intergenic deletion
between genes ADAMTS9 and MAGI1 (purple dot) shows a signiﬁcant
association that withstands multiple test correction.
Table 1 Phenotypic summary of GWAS and replication patient
cohorts
Characteristic
GWAS
cohort
Replication
cohort
Gender (% female) 45.3% 48.6%
Age (mean±SD) 52.9
±12.8
54.4±13.2
Chronic plaque psoriasis (%) 92.0% 90.9%
Age at onset psoriasis (mean±SD) 33.9
±15.4
35.7±15.5
Age at onset PsA (mean±SD) 42.5
±13.5
42.6±15.1
RF positive (%) 0% 0%
Fulfilling Classification Criteria for
Psoriatic Arthritis criteria
100% 100%
GWAS, genome-wide association studies; PsA, psoriatic arthritis; RF, rheumatoid
factor.
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GWAS in PsA or any other related disease. After correcting for
the number of CNVs analysed, the deletion association was still
found to be signiﬁcantly associated with PsA risk (p=0.023,
Bonferroni multiple test correction). Consequently, we selected
this region for replication in the independent data set of patients
and controls. In the remaining group of CNVs, we found 12
additional CNV regions nominally associated with PsA risk
(p<0.05, see online supplementary table S3). However, after
multiple test correction none of these variants was statistically
signiﬁcant and therefore they were not selected for replication.
Additionally, evaluating the concordance between these CNVs
and neighbouring SNPs, we did not ﬁnd a strong linkage dis-
equilibrium (LD) (r2>0.8) with markers previously associated
with PsA, Ps or other autoimmune diseases.
CNV replication in the validation cohorts
The deletion genotypes determined using the quantitative
RT-PCR assays showed a 100% concordance with the number
of copies (0, 1 or 2) estimated using sequencing. We subse-
quently used these two RT-PCR assays to genotype an
independent cohort of 1133 patients with PsA and 1831 con-
trols. We replicated the association of the ADAMTS9-MAGI1
intergenic deletion with PsA risk (p=0.032, OR (95% CI) 1.3
(1.0 to 1.7), meta-analysis p=5.97e-5, OR (95% CI) 1.48
(1.21 to 1.82)).
Finally, comparing the frequencies of ADAMTS9-MAGI1 dele-
tion of patients with PsA with patients with PsC, we also found
a statistically signiﬁcant increase of the deletion in the group of
patients with PsA similar to that observed when comparing to
healthy controls (freq PsA=11.0%, freq PsC=7.7%, freq con-
trols=8.8%, p=0.0088). Accordingly, when comparing patients
with PsC to healthy controls, we did not ﬁnd a statistically sig-
niﬁcant difference between the deletion frequencies of groups
(p=0.33).
ADAMTS9-MAGI1 deletion sequence characterisation
Using a next-generation sequencing approach, we characterised
the deletion region in chromosome 3q14.2 associated with PsA
risk. Using a sample of 100 patients with PsA and 100 controls
selected to have a higher frequency of the deletion (in total, 100
deletion carriers vs 100 2N individuals), we determined the
physical extent and molecular nature of ADAMTS9-MAGI1 dele-
tion polymorphism. PCR capture and sequencing of the dele-
tion breakpoints revealed that the deletion removes 25 879
nucleotides (ﬁgure 1D).
In order to explore the LD pattern associated with the dele-
tion and the relation with the two ﬂanking genes, we sequenced
ADAMTS9 and MAGI1 genes and their proximal 50 and 30
untranslated regions. LD analysis showed clearly that only very
few close polymorphisms have moderate to high correlation
with the deletion (r2>0.7, n=20 SNPs, ﬁgure 3). From the
>18 000 DNA variants identiﬁed after sequencing both
ADAMTS9 and MAGI1 genes, none showed a signiﬁcant LD
with the deletion (ﬁgure 3).
DISCUSSION
GWAS based on SNPs have been highly successful in identifying
genetic variants associated with the risk to develop psoriasis and
PsA. However, there is still a large fraction of the genetic basis
of PsA that has not been identiﬁed. In the present study, we
have performed a GWAS of CNVs to identify new genomic loci
associated with PsA risk. Using a discovery cohort of Spanish
patients with PsA and controls, we have found a signiﬁcant asso-
ciation of a deletion located between ADAMTS9 and MAGI1
genes with PsA risk. We have subsequently validated this associ-
ation in an independent cohort of patients and controls.
Furthermore, using a cohort of patients with psoriasis without
concomitant arthritis we provide evidence that the deletion is
speciﬁc for PsA.
ADAM metallopeptidase with thrombospondin type 1 motif 9
(ADAMTS9) gene belongs to a family of enzymes specialised in
the degradation of the extracellular matrix. In particular,
ADAMTS9 belongs to the family of the aggrecanases (which
also includes ADAMTS-1, ADAMTS-4, ADAMTS-6,
ADAMTS-8 and ADAMTS-15) that are specialised in the deg-
radation of aggrecan, one of the main proteoglycan constituents
of the cartilage extracellular matrix.28 Aggrecanase activity has
been found to be associated with cartilage degradation in
inﬂammatory joint diseases including PsA.29 30 Importantly, in
vitro studies with chondrocytes have found that after stimula-
tion with tumour necrosis factor (TNF)-α and interleukin
(IL)-1, two of the most abundant cytokines in PsA synovium,31
Figure 3 Pairwise linkage disequilibrium (LD) between the deletion and ﬂanking sequence variants. The LD (r2) between the deletion and the
>18 000 variants identiﬁed after sequencing the regions ﬂanking the copy number variants as well as ADAMTS9 and MAGI1 loci. From these
results, it is clear that only a small proportion of close variants show a high correlation with the deletion (ie, r2>0.9, centre region of the plot) and
that there is no variant within the transcribed or the ﬂanking regions of ADAMTS9 (left region) or MAGI1 (right region) that could explain the
observed association. The 3p14.1 chromosome regions between these three loci and that were not sequenced are left blank.
Julià A, et al. Ann Rheum Dis 2015;74:1875–1881. doi:10.1136/annrheumdis-2014-207190 1879
Clinical and epidemiological research
group.bmj.com on November 29, 2016 - Published by http://ard.bmj.com/Downloaded from 
ADAMTS9 was clearly the most highly induced among all the
different aggrecanases.32 33 Consequently, genetic variants that
inﬂuence the rates of matrix turnover in the cartilage and bone
of the inﬂamed synovial joint could be crucial in determining
the level of tissue degradation in PsA.
Membrane-associated guanylate kinase, WW and PDZ domain
containing 1 (MAG1) is a member of the membrane-associated
guanylate kinase family of genes. MAGI1 is known to be
expressed in cell-to-cell contacts, acting as a scaffold protein to
stabilise cadherin-mediated adhesions and has been found to be
expressed in epithelial and endothelial tight junctions.34 MAGI1
activity has been related to several pathological junction-
associated processes, including oncogenic35 as well as virus-
associated invasiveness.36 To date, there is no evidence of a
direct implication of MAGI1 in PsA pathology or, even, in auto-
immune diseases. There is evidence, however, that MAGI1
interacts with phosphatase and tensin homologue protein, a sig-
nalling protein that participates in the negative regulation of
regulatory T cells (Tregs),37 which are master inhibitors of auto-
immunity. While the implication of Treg has been clearly
deﬁned in rheumatoid arthritis or psoriasis aetiology,38 there are
yet no studies directly analysing the implication of this key
immune regulator in PsA,39 although there is recent evidence of
their activity in the disease pathology.40 Clearly, future studies
aimed at characterising the implication of MAGI1 activity in
autoimmunity are necessary.
The deep sequence analysis found that there is very little cor-
relation between the ∼26 kb intergenic deletion associated with
PsA risk and the polymorphisms located in the transcribed
sequences and proximal regions of ADAMTS9 and MAGI1
genes. Also, our sequencing analysis clearly shows that very few
neighbouring markers are in moderate or high LD with this
CNV, suggesting that the deletion itself is the genetic variant
implicated in the aetiology of PsA. Exploration of the chromo-
some 3q14.2 deleted region in multiple biomedical databases
including ENCODE41 did not show regulatory evidence asso-
ciated with this variation. Also analysing available cis and
trans-eQTL regulatory data sets42 we did not ﬁnd an association
between this deletion and the expression of other genes.
However, it is increasingly becoming evident that a large frac-
tion of regulatory variants in the genome will be only detected
under the speciﬁc target tissue where they are expressed and,
perhaps, only under the adequate stimulation.43 For example,
ADAMTS9 expression in chondrocytes was found to be
expressed only after stimulation by proinﬂammatory cytokines
TNF and IL-1.32 Additional studies aimed at characterising the
functional implications of this deletion and their role in PsA
aetiology are therefore warranted.
To date, there is evidence that the frequency and penetrance
of multiple risk loci in PsA and psoriasis risk is different popu-
lations with different ancestries.44 It will be therefore necessary
to evaluate the frequency and effect size of this deletion at
3p14.2 in other non-Caucasian populations. Also, the associ-
ation of the ADAMTS9-MAGI1 CNV with different PsA
phenotypes could be of high relevance. In our discovery
cohort, we analysed the association of the deletion with axial
disease, arthritis mutilans, gender, age of start of the disease
and PsA familial aggregation, but we did not ﬁnd a signiﬁcant
association (data not shown). These results support that the
deletion at chromosome 3q14.2 is speciﬁcally associated to the
risk to develop PsA. It is possible, however, that once the
speciﬁc biological mechanisms inﬂuenced by this genetic
variation are identiﬁed, more targeted analysis will reveal
association to other PsA phenotypes.
In the present study, we have performed the ﬁrst CNV GWAS
in PsA. We have identiﬁed a new deletion in ADAMTS9-MAGI1
locus associated with PsA risk and we have validated this associ-
ation in an independent patient and control cohort.
Additionally, using a cohort of patients with PsC we have
demonstrated that the variation is speciﬁcally associated with
the development of PsA. The present study represents an
important step in the characterisation of the common genetic
variation associated with PsA.
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